EP1363611A1 - Therapie de l'hepatite aux retinoides - Google Patents

Therapie de l'hepatite aux retinoides

Info

Publication number
EP1363611A1
EP1363611A1 EP02707670A EP02707670A EP1363611A1 EP 1363611 A1 EP1363611 A1 EP 1363611A1 EP 02707670 A EP02707670 A EP 02707670A EP 02707670 A EP02707670 A EP 02707670A EP 1363611 A1 EP1363611 A1 EP 1363611A1
Authority
EP
European Patent Office
Prior art keywords
hepatitis
therapeutically effective
retinoic acid
effective amount
trans retinoic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02707670A
Other languages
German (de)
English (en)
Other versions
EP1363611A4 (fr
Inventor
Anthony H. DYAX Corp. WILLIAMS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aronex Pharmaceuticals Inc
Original Assignee
Aronex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aronex Pharmaceuticals Inc filed Critical Aronex Pharmaceuticals Inc
Publication of EP1363611A1 publication Critical patent/EP1363611A1/fr
Publication of EP1363611A4 publication Critical patent/EP1363611A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention is drawn to a method of treating hepatitis comprising
  • the amount of retinoid such as all- trans retinoic acid.
  • the retinoid such as all- trans retinoic acid.
  • hepatitis form of hepatitis is viral hepatitis caused by infection with A, B, C, D, E, and G
  • Hepatitis is an inflammatory liver disease. It is associated with loss of
  • liver may become enlarged and jaundice may be present. Both chronic and acute
  • hepatitis is known.
  • the acute form subsides, generally after about
  • liver disease such as cirrhosis or hepatocellular carcinoma.
  • Type A was previously termed infectious
  • Type B was previously termed serum hepatitis
  • Type C was non-
  • Type D was delta hepatitis.
  • viruses have been known to exhibit hepatitis as a secondary effect. These viruses include Cytomegalovirus, Epstein-Barr virus, as well as Yellow Fever.
  • Hepatitis is also a secondary effect of certain parasites and bacteria infections.
  • Non-viral hepatitis is also associated with autoimmune diseases, Wilson's
  • hemochromatosis and those diseases of toxic origin such as drug,
  • Hepatitis B and C were not drawn.
  • Hepatitis C was not drawn.
  • non-A non-B hepatitis
  • RNA virus of the type described as "Flavivirus” is the cause of Hepatitis C. This
  • RNA virus has been described as a 40-50 nanometer linear single-strand RNA
  • lipid envelope (ribonucleic acid) virus with a lipid envelope.
  • the lipid envelope In native state, the lipid envelope is
  • Hepatitis B is caused by a double
  • stranded DNA virus of the type known as Hepadnavirus . It is a 42 nm particle
  • enterovirus is classified as a genus of the
  • Picornaviridae This genus is generally divided into five major groups.
  • Enteroviruses are characterized by a high degree of genetic diversity at the VP1
  • This invention comprises a method of treating hepatitis comprising
  • a ⁇ - trans retinoic acid (inter alia, liposomal all- trans retinoic acid) of at least about 10mg at least about every other day.
  • retinoic acid are variously at least about 10 mg/m 2 , at least about 15 mg/m 2 , at
  • This method is particularly useful in hepatitis
  • viral hepatitis including hepatitis A, B, C, D, E, or G.
  • This invention also comprises a method of treating hepatitis comprising
  • this includes retinoid in liposomal
  • This invention yet further comprises a method of treating enteroviral
  • this includes retinoid in liposomal form, and further in
  • therapeutically effective amount optionally at least about every other day.
  • group consisting of (i) poliovirus, (ii) group A coxsackievirus, (iii) group B
  • Echovirus 3 4, 6, 7, 9 or 1 1
  • chronic viral disease in a subject comprising administering to said subject a
  • retinoid is at least about 50mg at least about every other day.
  • ATRA refers to a ⁇ -trans retinoic acid, a retinoid. Retinoids in general
  • retinoids include trans-retinoic acid and all- trat?s-retinol.
  • Other retinoids are retinoic acid
  • retinol retinol, retinyl acetate, retinaldehyde, all-trans-retinoic acid, and 13-cis-retinoic
  • Non-liposomal retinoids often suitable for oral administration, are referred to
  • Liposomal ATRA or retinoid shall be broadly understood to encompass
  • lipids are generally spherical structures comprising lipids, fatty acids, lipid bilayer type
  • liposomes are completely closed lipid bilayer membranes containing an entrapped
  • Liposomes may be unilamellar vesicles (possessing a single
  • bilayer membrane or multilamellar vesicles (onion-like structures characterized
  • the bilayer is composed of two lipid monolayers having a hydrophobic
  • bilayer is such that the hydrophobic (nonpolar) "tails" of the lipid monolayers
  • Liposomes are vesicles composed of one or more concentric phospholipid
  • bilayers and used medically especially to deliver a drug into the body.
  • liposome and liposomal.
  • liposome By way of example of such nonliposomal lipid
  • L-ATRA liposomal-ATRA
  • retinoids as
  • liposomal- ATRA or "-retinoid” shall extend to
  • Hepatitis shall be broadly construed in reference to inflammatory liver
  • viral hepatitis are also contemplated within this invention.
  • Therapeutically effective amount as to a drug dosage shall mean that
  • a therapeutically effective amount shall include
  • effective amount is about 50 to about 150 mg administered at least about every
  • a therapeutically effective amount shall mean about
  • ATRA is about 50 to about 150 mg administered at least about every other day.
  • anti-cancer activities retinoids, including ATRA act to reduce the viral load in
  • hepatitis patients with particular reference to hepatitis B and C.
  • hepatitis B and C hepatitis B and C.
  • liposomal retinoid such as L-ATRA is effective.
  • C hepatic enzymes (SPGT and SGOT), bilirubin, and alkaline phosphatase).
  • a 34 year old female is diagnosed by serological tests as positive for
  • hepatitis C hepatic
  • a 54 year old male is diagnosed by serological tests as positive for
  • hepatitis A hepatic enzymes
  • APL started to receive L-ATRA (ATRAGEN ® ) QOD at 90 mg/m 2 .
  • ATRAGEN ® L-ATRA
  • liver function test liver function test
  • HCR hematologic complete remission
  • compositions of this invention possess valuable pharmacological properties
  • enteroviruses and hepatitis associated viruses in human and veterinary medicine.
  • Administration is contemplated to include chronic, acute or intermittent
  • compositions are particularly useful in treating hepatitis A, B, C, D, E,
  • compositions can be used in ]n vitro methodologies,
  • diagnostics or screening procedures e.g., in an assay drawn to sensitive
  • the present invention can be employed in admixture with carriers, excipients and
  • compositions of this invention are generally administered to animals,
  • mammals including but not limited to mammals such as livestock, household pets,
  • injectable particularly suitable are injectable.
  • sterile for parenteral application, particularly suitable are injectable.
  • solutions preferably oily or aqueous solutions, as well as suspensions,
  • emulsions or implants, including suppositories.
  • Ampules are convenient unit
  • liquids drops, suppositories, or capsules.
  • a syrup, elixir, or the like can be used
  • compositions of this invention can be any suitable pharmacologically active compositions of this invention.
  • compositions of this invention can be employed in admixture with
  • carrier substances suitable for parenteral e.g., enteral (e.g., oral or inhalation) or
  • Suitable pharmaceutically acceptable carriers include but are not limited to
  • compositions can be any suitable pharmaceutical preparations.
  • the pharmaceutical preparations can be any suitable pharmaceutical preparations.
  • auxiliary agents e.g. They can also be
  • antiviral drugs such as alpha interferon, ribavirin, amantadine,
  • ganciclovir dideoxycytosine, dideoxyinosine
  • rimantadine stavudine, famciclovir, and trifluridine.
  • dosage forms include
  • injectable, sterile are particularly suitable are injectable, sterile
  • solutions preferably suspensions.
  • Ampules are convenient unit dosages.
  • Sustained or directed release compositions can be formulated, e.g.,
  • degradable coatings e.g., by microencapsulation, multiple coatings, etc. It is
  • compositions of this invention are dispensed in unit dosage
  • liposomal ATRA of from 1 5 to 300 or more mg/m 2 and
  • compositions in a specific case will vary according to the specific compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une méthode de traitement de l'hépatite, consistant à administrer à un sujet une quantité thérapeutiquement efficace de rétinoïdes, tels que de l'acide tout-trans rétinoïque. Dans des modes de réalisation particuliers, la forme d'hépatite est l'hépatite A, B, C, D, E et G et le traitement s'effectue au moyen d'acide tout-trans rétinoïque liposomal.
EP02707670A 2001-02-02 2002-01-31 Therapie de l'hepatite aux retinoides Withdrawn EP1363611A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26597701P 2001-02-02 2001-02-02
US265977P 2001-02-02
PCT/US2002/002996 WO2002066022A1 (fr) 2001-02-02 2002-01-31 Therapie de l'hepatite aux retinoides

Publications (2)

Publication Number Publication Date
EP1363611A1 true EP1363611A1 (fr) 2003-11-26
EP1363611A4 EP1363611A4 (fr) 2004-08-11

Family

ID=23012660

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02707670A Withdrawn EP1363611A4 (fr) 2001-02-02 2002-01-31 Therapie de l'hepatite aux retinoides

Country Status (4)

Country Link
EP (1) EP1363611A4 (fr)
JP (1) JP2004522770A (fr)
CA (1) CA2437168A1 (fr)
WO (1) WO2002066022A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2509955A1 (fr) * 2002-11-29 2004-06-17 Gpc Biotech Ag Formulations utiles pour lutter contre les infections par le virus de l'hepatite c
DE10305138A1 (de) * 2003-02-07 2004-08-26 Axxima Pharmaceuticals Ag Gegen Hepatitis C-Virusinfektionen nützliche Verbindungen und Substanzen
WO2005120479A1 (fr) * 2004-06-09 2005-12-22 Gpc Biotech Ag Utilisation de selenium ou d'un sel de selenium et d'un acide retinoique ou d'un retinoide pour traiter une hepatite c virale
WO2018054891A1 (fr) * 2016-09-20 2018-03-29 Ruprecht-Karls-Universität Composés et leurs combinaisons de prévention et/ou de traitement d'infections par le hbv et/ou le hdv

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811119A (en) * 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
US5824313A (en) * 1989-09-25 1998-10-20 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US6028088A (en) * 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
WO2002015920A2 (fr) * 2000-08-17 2002-02-28 University Of Sheffield Traitement des maladies d'hyperproliferation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166319A (en) * 1989-10-10 1992-11-24 Brunswick Corporation Interfacial condensation of bioactive compounds and the site-specific compounds and conjugates thereof
US5789441A (en) * 1996-02-15 1998-08-04 Virocell Inc. Leukotriene B4 as an antiviral and anti-neoplastic agent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811119A (en) * 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
US5824313A (en) * 1989-09-25 1998-10-20 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US6028088A (en) * 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
WO2002015920A2 (fr) * 2000-08-17 2002-02-28 University Of Sheffield Traitement des maladies d'hyperproliferation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ERKEK E ET AL: "Psoriasis associated with HCV and exacerbated by interferon alpha: complete clearance with acitretin during interferon alpha treatment for chronic active hepatitis." DERMATOLOGY (BASEL, SWITZERLAND) 2000, vol. 201, no. 2, 2000, pages 179-181, XP009031636 ISSN: 1018-8665 *
See also references of WO02066022A1 *

Also Published As

Publication number Publication date
WO2002066022A1 (fr) 2002-08-29
JP2004522770A (ja) 2004-07-29
EP1363611A4 (fr) 2004-08-11
CA2437168A1 (fr) 2002-08-29

Similar Documents

Publication Publication Date Title
RU2659729C2 (ru) Кохлеаты, полученные с использованием фосфатидилсерина сои
AU2023204000A1 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
EP1845987A2 (fr) Traitement des troubles inflammatoires avec du praziquantel
WO2010128889A1 (fr) Composition pharmaceutique comprenant de l'arbidol sous forme de nanoparticules de phospholipides
BRPI0618529A2 (pt) meio antiviral, abrangendo zeólitos ativados em forma tribomecánica, própolis e colostro
WO2006105155A2 (fr) Administration de glutathion (reduit) par intraveineuse ou encapsule dans des liposomes pour le traitement des effets du tnf-$g(a) et des symptomes viraux pseudogrippaux
JPH07509730A (ja) ウイルス感染の治療におけるジデオキシヌクレオシドアナローグの使用
US20230263748A1 (en) Application of benflumetol and derivatives thereof in treatment of coronavirus infection
WO2002066022A1 (fr) Therapie de l'hepatite aux retinoides
RU2738719C1 (ru) Средство для лечения коронавирусных, ретровирусных инфекций и гепатита с
CN1329497A (zh) 对乙型肝炎病毒的联合治疗
US20040127566A1 (en) Retinoid hepatitis therapy
JPH05331061A (ja) アポトーシス誘起剤
JPS63500944A (ja) ウイルスの不活化
JP2002535371A (ja) リバビリンによる免疫応答の調節
CN106727480A (zh) Fex－3在制备抗肥胖症药物中的应用
WO1989001764A1 (fr) Palliatif destine au syndrome d'immunodeficience acquise/complexe relatif au syndrome d'immunodeficience acquise
CN101019872B (zh) 抗病毒纳米脂质体药物及其制备方法
JP2007506645A (ja) 抗腫瘍および抗転移のための製剤の製造におけるｎ−アセチル−ｄ−グルコサミンの使用
CN1504191A (zh) 葫芦素脂质体组方及其制剂
DE3780157T2 (de) Verwendung von 4-butyl-1,2-diphenyl-pyrazolidin-3,5-dion als antivirales arzneimittel gegen aids.
US20100016244A1 (en) D-glucopyranose 1-[3,5-bis (1,1-dimethylethy)-4-hydroxybenzoate] and its derivatives, preparation and use thereof
CN107281199A (zh) N‑乙酰‑d‑氨基葡萄糖及其药物可接受盐在制备治疗病毒性肝炎药物中的应用及药物
US20230129386A1 (en) Treatment of covid-19 with reverse micelle system comprising unmodified oligonucleotides
RU2104023C1 (ru) Лекарственное средство для лечения ретровирусных инфекций

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030901

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1060306

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20040625

17Q First examination report despatched

Effective date: 20041020

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050303

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1060306

Country of ref document: HK